CD4 and HIV-1 infection: In a phase III study involving 40 adult patients who had advanced disease and limited treatment options with MDR HIV-1 infection, the primary end point was reached that 33 (83%) achieved a decrease in viral load of at least 0.5 log10 copies/ml during a 7-day treatment period, and iMab in combination with an optimized background regimen significantly reduced the viral load and increased CD4 count at week 25 (Emu et al., 2018).